SCHEMBL25914384

SCHEMBL25914384

O=S(=O)(O)Cc1nc(-c2ccc(Br)cc2)no1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 3/20 0.56
TSHR P16473 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
LMNA P02545 2/20 0.49
HTT P42858 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NR1H4 Q96RI1 1/20 0.47
TP53 P04637 2/20 0.46
MAPT P10636 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
THRB P10828 1/20 0.46
NOTUM Q6P988 3/20 0.45
ALOX15 P16050 1/20 0.44
AKR1B1 P15121 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29254346 0.98 SIRT2 (0.55) SIRT2TSHRSMN1; SMN2TDP1LMNA
SCHEMBL25914388 0.85 NOTUM (0.65) SIRT2TSHRSMN1; SMN2TDP1LMNA
SCHEMBL25914386 0.85 NPC1 (0.56) SIRT2TSHRSMN1; SMN2LMNAHTT
SCHEMBL30195932 0.84 SIRT2 (0.55) SIRT2TSHRSMN1; SMN2TDP1LMNA
SCHEMBL28869663 0.77 SIRT2 (0.71) SIRT2TSHRSMN1; SMN2TDP1LMNA
SCHEMBL22530395 0.76 SIRT2 (0.56) SIRT2TSHRSMN1; SMN2TDP1LMNA
SCHEMBL15299292 0.76 SIRT2 (0.64) SIRT2TSHRSMN1; SMN2TDP1LMNA
SCHEMBL10937283 0.76 SIRT2 (0.71) SIRT2TSHRSMN1; SMN2TDP1LMNA
SCHEMBL6328232 0.75 TSHR (0.74) SIRT2TSHRSMN1; SMN2LMNATP53
SCHEMBL25914397 0.74 HDAC6 (0.48) SMN1; SMN2LMNAHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 US disclosed
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718592-B2 Oxadiazole derivative OXA1L, SCN1A, CACNA1A SIRT2 291/4885TSHR 2480/4885SMN1; SMN2 876/4885
US-20230265061-A1 OXADIAZOLE DERIVATIVE OXA1L, SCN1A, CACNA1A SIRT2 291/4885TSHR 2480/4885SMN1; SMN2 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.